Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL - a podcast by PVI, PeerView Institute for Medical Education
from 2022-05-04T02:14:22.670054
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval and use of several novel agent classes in indolent and aggressive non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Cite molecular-, disease-, or patient-related factors that can guide therapeutic selection and prognosis in patients with FL or DLBCL, Summarize current safety and efficacy evidence surrounding novel therapeutic classes, including targeted/epigenetic agents, IMiDs, antibodies, and CAR-T cell therapy, used to treat FL or DLBCL, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory FL or DLBCL with consideration of baseline risk factors and patient/disease characteristics, Develop a management plan for the unique adverse events associated with the use of novel therapies in patients with FL or DLBCL.
Further episodes of PeerView Immunology
Further podcasts by PVI, PeerView Institute for Medical Education